Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

FDA Approves Extended-Release Version of HIV Drug

April 6, 2011

The Food and Drug Administration has approved an extended-release form of the HIV drug nevirapine. Boehringer Ingelheim Pharmaceuticals' Viramune XR is a 400 mg tablet taken once daily; the earlier version required twice-daily dosing. "Viramune XR is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults," FDA said. Patients needing financial assistance to access the drug are asked to telephone 800-556-8317 or visit www.RxHope.com. To read FDA's statement, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm248800.htm.

Back to other news for April 2011

Adapted from:
Hartford Courant
04.04.2011; Rinker Buck


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
Approval of Viramune XR (Nevirapine) 400 mg Extended Release Tablet
More on HIV Medications
More News on Nevirapine (Viramune)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement